Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1991 Jun;35(6):1181–1185. doi: 10.1128/aac.35.6.1181

In vitro susceptibilities of Mycoplasma pneumoniae, Mycoplasma hominis, and Ureaplasma urealyticum to sparfloxacin and PD 127391.

K B Waites 1, L B Duffy 1, T Schmid 1, D Crabb 1, M S Pate 1, G H Cassell 1
PMCID: PMC284307  PMID: 1929260

Abstract

The in vitro activities of two investigational quinolones, sparfloxacin (previously designated AT 4140) and PD 127391, were determined for 30 strains each of Mycoplasma pneumoniae, Mycoplasma hominis, and Ureaplasma urealyticum and compared with those of ciprofloxacin, tetracycline, clindamycin, and erythromycin. Erythromycin was the most active compound against M. pneumoniae (maximum MIC, less than 0.008 microgram/ml). PD 127391 (MICs, less than 0.008 to 0.031 microgram/ml), sparfloxacin (MICs, less than 0.008 to 0.25 microgram/ml), clindamycin (MICs, less than 0.008 to 0.5 microgram/ml), and tetracycline (MICs, 0.063 to 0.25 microgram/ml) were superior to ciprofloxacin (MICs, 0.5 to 2 microgram/ml). Sparfloxacin and PD 127391 were active against M. hominis (MICs, less than 0.008 to 0.031 microgram/ml for each) at concentrations comparable to those of clindamycin (MICs, less than 0.008 to 0.063 microgram/ml) and at concentrations lower than those of ciprofloxacin (MICs, 0.125 to 0.5 microgram/ml). As expected, M. hominis was resistant to erythromycin (MICs, 32 to greater than or equal to 256 micrograms/ml). For U. urealyticum, PD 127391 (MICs, 0.031 to 0.5 microgram/ml) and sparfloxacin (MICs, 0.063 to 1 microgram/ml) were superior to erythromycin (MICs, 0.25 to 4 micrograms/ml), ciprofloxacin (MICs, 0.5 to 8 micrograms/ml), and clindamycin (MICs, 0.25 to 64 micrograms/ml. Both new quinolones were equally active against tetracycline-susceptible as well as resistant strains of M. hominis and U. urealyticum. The possible influence of medium components and/or pH on MICs was evaluated by testing a Staphylococcus aureus reference strain with each antibiotic in SP-4 broth and 10-B broth and comparing the results with published MICs for this strain. MICs determined in 10-B broth for erythromycin were affected most. This study shows that the activities of sparfloxacin and PD 127391 are similar to one another and comparable or superior to those of other drugs used to treat mycoplasmal infections. The MICs of both new quinolones were consistently 2 to several dilutions lower than those of ciprofloxacin for each species.

Full text

PDF
1181

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aznar J., Caballero M. C., Lozano M. C., de Miguel C., Palomares J. C., Perea E. J. Activities of new quinoline derivatives against genital pathogens. Antimicrob Agents Chemother. 1985 Jan;27(1):76–78. doi: 10.1128/aac.27.1.76. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Cantet P., Renaudin H., Quentin C., Bebear C. Activité comparée in vitro de sept quinolones sur Ureaplasma urealyticum. Pathol Biol (Paris) 1983 Jun;31(6):501–503. [PubMed] [Google Scholar]
  3. Cassell G. H., Crouse D. T., Waites K. B., Rudd P. T., Davis J. K. Does Ureaplasma urealyticum cause respiratory disease in newborns? Pediatr Infect Dis J. 1988 Aug;7(8):535–541. [PubMed] [Google Scholar]
  4. Cassell G. H., Davis J. K., Waites K. B., Rudd P. T., Talkington D., Crouse D., Horowitz S. A. Pathogenesis and significance of urogenital mycoplasmal infections. Adv Exp Med Biol. 1987;224:93–115. doi: 10.1007/978-1-4684-8932-3_10. [DOI] [PubMed] [Google Scholar]
  5. Cassell G. H., Waites K. B., Crouse D. T., Rudd P. T., Canupp K. C., Stagno S., Cutter G. R. Association of Ureaplasma urealyticum infection of the lower respiratory tract with chronic lung disease and death in very-low-birth-weight infants. Lancet. 1988 Jul 30;2(8605):240–245. doi: 10.1016/s0140-6736(88)92536-6. [DOI] [PubMed] [Google Scholar]
  6. Cassell G. H., Waites K. B., Pate M. S., Canupp K. C., Duffy L. B. Comparative susceptibility of Mycoplasma pneumoniae to erythromycin, ciprofloxacin, and lomefloxacin. Diagn Microbiol Infect Dis. 1989 Sep-Oct;12(5):433–435. doi: 10.1016/0732-8893(89)90115-6. [DOI] [PubMed] [Google Scholar]
  7. Cummings M. C., McCormack W. M. Increase in resistance of Mycoplasma hominis to tetracyclines. Antimicrob Agents Chemother. 1990 Dec;34(12):2297–2299. doi: 10.1128/aac.34.12.2297. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Dobson R. A., O'Connor J. R., Poulin S. A., Kundsin R. B., Smith T. F., Came P. E. In vitro antimicrobial activity of rosoxacin against Neisseria gonorrhoeae, Chlamydia trachomatis, and Ureaplasma urealyticum. Antimicrob Agents Chemother. 1980 Nov;18(5):738–740. doi: 10.1128/aac.18.5.738. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Evans R. T., Taylor-Robinson D. The incidence of tetracycline-resistant strains of Ureaplasma urealyticum. J Antimicrob Chemother. 1978 Jan;4(1):57–63. doi: 10.1093/jac/4.1.57. [DOI] [PubMed] [Google Scholar]
  10. Fallon R. J., Brown W. M. In-vitro sensitivity of legionellas, meningococci and mycoplasmas to ciprofloxacin and enoxacin. J Antimicrob Chemother. 1985 Jun;15(6):787–789. doi: 10.1093/jac/15.6.787. [DOI] [PubMed] [Google Scholar]
  11. Freeman S., Wormuth J., Cornett J. In vitro activity of amifloxacin against Chlamydia trachomatis and Ureaplasma urealyticum. Eur J Clin Microbiol. 1985 Oct;4(5):515–516. doi: 10.1007/BF02014440. [DOI] [PubMed] [Google Scholar]
  12. Hoban D., DeGagne P., Witwicki E. In vitro activity of lomefloxacin against Chlamydia trachomatis, Neisseria gonorrhoeae, Haemophilus ducreyi, Mycoplasma hominis, and Ureaplasma urealyticum. Diagn Microbiol Infect Dis. 1989 May-Jun;12(3 Suppl):83S–86S. doi: 10.1016/0732-8893(89)90071-0. [DOI] [PubMed] [Google Scholar]
  13. Kenny G. E., Cartwright F. D. Susceptibility of Mycoplasma pneumoniae to several new quinolones, tetracycline, and erythromycin. Antimicrob Agents Chemother. 1991 Mar;35(3):587–589. doi: 10.1128/aac.35.3.587. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Kenny G. E., Hooton T. M., Roberts M. C., Cartwright F. D., Hoyt J. Susceptibilities of genital mycoplasmas to the newer quinolones as determined by the agar dilution method. Antimicrob Agents Chemother. 1989 Jan;33(1):103–107. doi: 10.1128/aac.33.1.103. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Krausse R., Ullmann U. Comparative in vitro activity of fleroxacin (RO 23-6240) against Ureaplasma urealyticum and Mycoplasma hominis. Eur J Clin Microbiol Infect Dis. 1988 Feb;7(1):67–69. doi: 10.1007/BF01962178. [DOI] [PubMed] [Google Scholar]
  16. Liebowitz L. D., Saunders J., Fehler G., Ballard R. C., Koornhof H. J. In vitro activity of A-56619 (difloxacin), A-56620, and other new quinolone antimicrobial agents against genital pathogens. Antimicrob Agents Chemother. 1986 Dec;30(6):948–950. doi: 10.1128/aac.30.6.948. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Lorian V., Sabath L. D. Effect of pH on the activity of erythromycin against 500 isolates of gram-negative bacilli. Appl Microbiol. 1970 Nov;20(5):754–756. doi: 10.1128/am.20.5.754-756.1970. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Mogabgab W. J., Holmes B., Murray M., Beville R., Lutz F. B., Tack K. J. Randomized comparison of ofloxacin and doxycycline for chlamydia and ureaplasma urethritis and cervicitis. Chemotherapy. 1990;36(1):70–76. doi: 10.1159/000238750. [DOI] [PubMed] [Google Scholar]
  19. Nakamura S., Minami A., Nakata K., Kurobe N., Kouno K., Sakaguchi Y., Kashimoto S., Yoshida H., Kojima T., Ohue T. In vitro and in vivo antibacterial activities of AT-4140, a new broad-spectrum quinolone. Antimicrob Agents Chemother. 1989 Aug;33(8):1167–1173. doi: 10.1128/aac.33.8.1167. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Osada Y., Ogawa H. Antimycoplasmal activity of ofloxacin (DL-8280). Antimicrob Agents Chemother. 1983 Mar;23(3):509–511. doi: 10.1128/aac.23.3.509. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Renaudin H., Quentin C., de Barbeyrac B., Bebear C. Activité in vitro de nouvelles quinolones sur les mycoplasmes pathogènes pour l'homme. Pathol Biol (Paris) 1988 May;36(5):496–499. [PubMed] [Google Scholar]
  22. Ridgway G. L., Mumtaz G., Gabriel F. G., Oriel J. D. The activity of ciprofloxacin and other 4-quinolones against Chlamydia trachomatis and Mycoplasmas in vitro. Eur J Clin Microbiol. 1984 Aug;3(4):344–346. doi: 10.1007/BF01977491. [DOI] [PubMed] [Google Scholar]
  23. Roberts M. C., Kenny G. E. TetM tetracycline-resistant determinants in Ureaplasma urealyticum. Pediatr Infect Dis. 1986 Nov-Dec;5(6 Suppl):S338–S340. doi: 10.1097/00006454-198611010-00032. [DOI] [PubMed] [Google Scholar]
  24. Shepard M. C., Lunceford C. D. Serological typing of Ureaplasma urealyticum isolates from urethritis patients by an agar growth inhibition method. J Clin Microbiol. 1978 Nov;8(5):566–574. doi: 10.1128/jcm.8.5.566-574.1978. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Simon C., Lindner U. In vitro activity of norfloxacin against Mycoplasma hominis and Ureaplasma urealyticum. Eur J Clin Microbiol. 1983 Oct;2(5):479–480. doi: 10.1007/BF02013911. [DOI] [PubMed] [Google Scholar]
  26. Taylor-Robinson D., Furr P. M. Clinical antibiotic resistance of Ureaplasma urealyticum. Pediatr Infect Dis. 1986 Nov-Dec;5(6 Suppl):S335–S337. doi: 10.1097/00006454-198611010-00031. [DOI] [PubMed] [Google Scholar]
  27. Taylor-Robinson D., Furr P. M., Webster A. D. Ureaplasma urealyticum in the immunocompromised host. Pediatr Infect Dis. 1986 Nov-Dec;5(6 Suppl):S236–S238. doi: 10.1097/00006454-198611010-00006. [DOI] [PubMed] [Google Scholar]
  28. Tjiam K. H., Wagenvoort J. H., van Klingeren B., Piot P., Stolz E., Michel M. F. In vitro activity of the two new 4-quinolones A56619 and A56620 against Neisseria gonorrhoeae, Chlamydia trachomatis, Mycoplasma hominis, Ureaplasma urealyticum and Gardnerella vaginalis. Eur J Clin Microbiol. 1986 Oct;5(5):498–501. doi: 10.1007/BF02017690. [DOI] [PubMed] [Google Scholar]
  29. Tully J. G. Laboratory diagnosis of Mycoplasma pneumoniae infections. Isr J Med Sci. 1981 Jul;17(7):644–647. [PubMed] [Google Scholar]
  30. Waites K. B., Cassell G. H., Canupp K. C., Fernandes P. B. In vitro susceptibilities of mycoplasmas and ureaplasmas to new macrolides and aryl-fluoroquinolones. Antimicrob Agents Chemother. 1988 Oct;32(10):1500–1502. doi: 10.1128/aac.32.10.1500. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Waites K. B., Figarola T. A., Schmid T., Crabb D. M., Duffy L. B., Simecka J. W. Comparison of agar versus broth dilution techniques for determining antibiotic susceptibilities of Ureaplasma urealyticum. Diagn Microbiol Infect Dis. 1991 May-Jun;14(3):265–271. doi: 10.1016/0732-8893(91)90041-d. [DOI] [PubMed] [Google Scholar]
  32. Waites K. B., Rudd P. T., Crouse D. T., Canupp K. C., Nelson K. G., Ramsey C., Cassell G. H. Chronic Ureaplasma urealyticum and Mycoplasma hominis infections of central nervous system in preterm infants. Lancet. 1988 Jan 2;1(8575-6):17–21. doi: 10.1016/s0140-6736(88)91002-1. [DOI] [PubMed] [Google Scholar]
  33. Yancey R. J., Jr, Klein L. K. In-vitro activity of trospectomycin sulphate against Mycoplasma and Ureaplasma species isolated from humans. J Antimicrob Chemother. 1988 Jun;21(6):731–736. doi: 10.1093/jac/21.6.731. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES